Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes
Antonio Farina(Université Claude Bernard Lyon 1), Jérôme Honnorat(Université Claude Bernard Lyon 1), Αναστασία Ζεκερίδου(Mayo Clinic), Amanda C. Guidon(Harvard University), Alberto Vogrig(University of Udine), Macarena Villagrán‐García(Université Claude Bernard Lyon 1), Sergio Muñiz‐Castrillo(Hospices Civils de Lyon), Bastien Joubert(Université Claude Bernard Lyon 1), Roser Velasco(Universitat Autònoma de Barcelona)
Cited by 118
Related Papers
A clinical approach to diagnosis of autoimmune encephalitis
|The Lancet Neurology|2016|4.4k
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
|Neurology Neuroimmunology & Neuroinflammation|2021|702
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter
|Neuro-Oncology|2022|508
Autoimmune Encephalitis Misdiagnosis in Adults
|JAMA Neurology|2022|278
Autoimmune glial fibrillary acidic protein astrocytopathy
|Current Opinion in Neurology|2019|241